Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma

Gaurav C. Parikh, Ali Imran Amjad, Rima M. Saliba, Syed M A Kazmi, Ziad U. Khan, Amit Lahoti, Chitra Hosing, Floralyn Mendoza, Suhail R. Qureshi, Donna M. Weber, Michael Wang, Uday Popat, Amin M. Alousi, Richard E. Champlin, Sergio A. Giralt, Muzaffar H. Qazilbash

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Approximately 20% of patients with multiple myeloma (MM) have renal failure at diagnosis, and about 5% are dialysis-dependent. Many of these patients are considered ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) because of a high risk of treatment-related toxicity. We evaluated the outcome of 46 patient with MM and renal failure, defined as serum creatinine >2 mg/dL sustained for >1 month before the start of preparative regimen. Patients received auto-HSCT at our institution between September 1997 and September 2006. Median serum creatinine and creatinine clearance (CrCl) at auto-HSCT were 2.9 mg/dL (range: 2.0-12.5) and 33 mL/min (range: 8.7-63), respectively. Ten patients (21%) were dialysis-dependent. Median follow-up in surviving patients was 34 months (range: 5-81). Complete (CR) and partial responses (PR) after auto-HSCT were seen in 9 (22%) and 22 (53%) of the 41 evaluable patients, with an overall response rate of 75%. Two patients (4%) died within 100 days of auto-HSCT. Grade 2-4 nonhematologic adverse events were seen in 18 patients (39%) and included cardiac arrythmias, pulmonary edema, and hyperbilirubinemia. Significant improvement in renal function, defined as an increase in flomerular filtration rate (GFR) by 25% above baseline, was seen in 15 patients (32%). Kaplan-Meier estimates of 3-year progression-free survival (PFS) and overall survival (OS) were 36% and 64%, respectively. In conclusion, auto HSCT can be offered to patients with MM and renal failure with acceptable toxicity and with a significant improvement in renal function in approximately one-third of the transplanted patients. In this analysis, a melphalan (Mel) dose of 200 mg/m2 was not associated with an increase in toxicity or nonrelapse (Mel) mortality (NRM).

Original languageEnglish (US)
Pages (from-to)812-816
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume15
Issue number7
DOIs
StatePublished - Jul 1 2009

Fingerprint

Hematopoietic Stem Cell Transplantation
Multiple Myeloma
Renal Insufficiency
Creatinine
Melphalan
Dialysis
Kidney
Hyperbilirubinemia
Kaplan-Meier Estimate
Pulmonary Edema
Serum
Disease-Free Survival
Cardiac Arrhythmias

Keywords

  • Autologous
  • Myeloma
  • Renal failure

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma. / Parikh, Gaurav C.; Amjad, Ali Imran; Saliba, Rima M.; Kazmi, Syed M A; Khan, Ziad U.; Lahoti, Amit; Hosing, Chitra; Mendoza, Floralyn; Qureshi, Suhail R.; Weber, Donna M.; Wang, Michael; Popat, Uday; Alousi, Amin M.; Champlin, Richard E.; Giralt, Sergio A.; Qazilbash, Muzaffar H.

In: Biology of Blood and Marrow Transplantation, Vol. 15, No. 7, 01.07.2009, p. 812-816.

Research output: Contribution to journalArticle

Parikh, GC, Amjad, AI, Saliba, RM, Kazmi, SMA, Khan, ZU, Lahoti, A, Hosing, C, Mendoza, F, Qureshi, SR, Weber, DM, Wang, M, Popat, U, Alousi, AM, Champlin, RE, Giralt, SA & Qazilbash, MH 2009, 'Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma', Biology of Blood and Marrow Transplantation, vol. 15, no. 7, pp. 812-816. https://doi.org/10.1016/j.bbmt.2009.03.021
Parikh, Gaurav C. ; Amjad, Ali Imran ; Saliba, Rima M. ; Kazmi, Syed M A ; Khan, Ziad U. ; Lahoti, Amit ; Hosing, Chitra ; Mendoza, Floralyn ; Qureshi, Suhail R. ; Weber, Donna M. ; Wang, Michael ; Popat, Uday ; Alousi, Amin M. ; Champlin, Richard E. ; Giralt, Sergio A. ; Qazilbash, Muzaffar H. / Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma. In: Biology of Blood and Marrow Transplantation. 2009 ; Vol. 15, No. 7. pp. 812-816.
@article{3772ad8623cd4e32961c3f10f563fd0c,
title = "Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma",
abstract = "Approximately 20{\%} of patients with multiple myeloma (MM) have renal failure at diagnosis, and about 5{\%} are dialysis-dependent. Many of these patients are considered ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) because of a high risk of treatment-related toxicity. We evaluated the outcome of 46 patient with MM and renal failure, defined as serum creatinine >2 mg/dL sustained for >1 month before the start of preparative regimen. Patients received auto-HSCT at our institution between September 1997 and September 2006. Median serum creatinine and creatinine clearance (CrCl) at auto-HSCT were 2.9 mg/dL (range: 2.0-12.5) and 33 mL/min (range: 8.7-63), respectively. Ten patients (21{\%}) were dialysis-dependent. Median follow-up in surviving patients was 34 months (range: 5-81). Complete (CR) and partial responses (PR) after auto-HSCT were seen in 9 (22{\%}) and 22 (53{\%}) of the 41 evaluable patients, with an overall response rate of 75{\%}. Two patients (4{\%}) died within 100 days of auto-HSCT. Grade 2-4 nonhematologic adverse events were seen in 18 patients (39{\%}) and included cardiac arrythmias, pulmonary edema, and hyperbilirubinemia. Significant improvement in renal function, defined as an increase in flomerular filtration rate (GFR) by 25{\%} above baseline, was seen in 15 patients (32{\%}). Kaplan-Meier estimates of 3-year progression-free survival (PFS) and overall survival (OS) were 36{\%} and 64{\%}, respectively. In conclusion, auto HSCT can be offered to patients with MM and renal failure with acceptable toxicity and with a significant improvement in renal function in approximately one-third of the transplanted patients. In this analysis, a melphalan (Mel) dose of 200 mg/m2 was not associated with an increase in toxicity or nonrelapse (Mel) mortality (NRM).",
keywords = "Autologous, Myeloma, Renal failure",
author = "Parikh, {Gaurav C.} and Amjad, {Ali Imran} and Saliba, {Rima M.} and Kazmi, {Syed M A} and Khan, {Ziad U.} and Amit Lahoti and Chitra Hosing and Floralyn Mendoza and Qureshi, {Suhail R.} and Weber, {Donna M.} and Michael Wang and Uday Popat and Alousi, {Amin M.} and Champlin, {Richard E.} and Giralt, {Sergio A.} and Qazilbash, {Muzaffar H.}",
year = "2009",
month = "7",
day = "1",
doi = "10.1016/j.bbmt.2009.03.021",
language = "English (US)",
volume = "15",
pages = "812--816",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma

AU - Parikh, Gaurav C.

AU - Amjad, Ali Imran

AU - Saliba, Rima M.

AU - Kazmi, Syed M A

AU - Khan, Ziad U.

AU - Lahoti, Amit

AU - Hosing, Chitra

AU - Mendoza, Floralyn

AU - Qureshi, Suhail R.

AU - Weber, Donna M.

AU - Wang, Michael

AU - Popat, Uday

AU - Alousi, Amin M.

AU - Champlin, Richard E.

AU - Giralt, Sergio A.

AU - Qazilbash, Muzaffar H.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Approximately 20% of patients with multiple myeloma (MM) have renal failure at diagnosis, and about 5% are dialysis-dependent. Many of these patients are considered ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) because of a high risk of treatment-related toxicity. We evaluated the outcome of 46 patient with MM and renal failure, defined as serum creatinine >2 mg/dL sustained for >1 month before the start of preparative regimen. Patients received auto-HSCT at our institution between September 1997 and September 2006. Median serum creatinine and creatinine clearance (CrCl) at auto-HSCT were 2.9 mg/dL (range: 2.0-12.5) and 33 mL/min (range: 8.7-63), respectively. Ten patients (21%) were dialysis-dependent. Median follow-up in surviving patients was 34 months (range: 5-81). Complete (CR) and partial responses (PR) after auto-HSCT were seen in 9 (22%) and 22 (53%) of the 41 evaluable patients, with an overall response rate of 75%. Two patients (4%) died within 100 days of auto-HSCT. Grade 2-4 nonhematologic adverse events were seen in 18 patients (39%) and included cardiac arrythmias, pulmonary edema, and hyperbilirubinemia. Significant improvement in renal function, defined as an increase in flomerular filtration rate (GFR) by 25% above baseline, was seen in 15 patients (32%). Kaplan-Meier estimates of 3-year progression-free survival (PFS) and overall survival (OS) were 36% and 64%, respectively. In conclusion, auto HSCT can be offered to patients with MM and renal failure with acceptable toxicity and with a significant improvement in renal function in approximately one-third of the transplanted patients. In this analysis, a melphalan (Mel) dose of 200 mg/m2 was not associated with an increase in toxicity or nonrelapse (Mel) mortality (NRM).

AB - Approximately 20% of patients with multiple myeloma (MM) have renal failure at diagnosis, and about 5% are dialysis-dependent. Many of these patients are considered ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) because of a high risk of treatment-related toxicity. We evaluated the outcome of 46 patient with MM and renal failure, defined as serum creatinine >2 mg/dL sustained for >1 month before the start of preparative regimen. Patients received auto-HSCT at our institution between September 1997 and September 2006. Median serum creatinine and creatinine clearance (CrCl) at auto-HSCT were 2.9 mg/dL (range: 2.0-12.5) and 33 mL/min (range: 8.7-63), respectively. Ten patients (21%) were dialysis-dependent. Median follow-up in surviving patients was 34 months (range: 5-81). Complete (CR) and partial responses (PR) after auto-HSCT were seen in 9 (22%) and 22 (53%) of the 41 evaluable patients, with an overall response rate of 75%. Two patients (4%) died within 100 days of auto-HSCT. Grade 2-4 nonhematologic adverse events were seen in 18 patients (39%) and included cardiac arrythmias, pulmonary edema, and hyperbilirubinemia. Significant improvement in renal function, defined as an increase in flomerular filtration rate (GFR) by 25% above baseline, was seen in 15 patients (32%). Kaplan-Meier estimates of 3-year progression-free survival (PFS) and overall survival (OS) were 36% and 64%, respectively. In conclusion, auto HSCT can be offered to patients with MM and renal failure with acceptable toxicity and with a significant improvement in renal function in approximately one-third of the transplanted patients. In this analysis, a melphalan (Mel) dose of 200 mg/m2 was not associated with an increase in toxicity or nonrelapse (Mel) mortality (NRM).

KW - Autologous

KW - Myeloma

KW - Renal failure

UR - http://www.scopus.com/inward/record.url?scp=66949136270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66949136270&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2009.03.021

DO - 10.1016/j.bbmt.2009.03.021

M3 - Article

C2 - 19539212

AN - SCOPUS:66949136270

VL - 15

SP - 812

EP - 816

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 7

ER -